Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313334461> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W4313334461 endingPage "2" @default.
- W4313334461 startingPage "1" @default.
- W4313334461 abstract "The use of chimeric antigen receptro T-cell therapy all over (CAR-T)-cell therapy in multiple myeloma (MM) showed early promising results in heavily pre-treated patient with limited treatment options [ [1] Berdeja J.G. Madduri D. Usmani S.Z. Jakubowiak A. Agha M. Cohen A.D. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet (London, England). 2021; 398: 314-324https://doi.org/10.1016/S0140-6736(21)00933-8 Abstract Full Text Full Text PDF PubMed Scopus (327) Google Scholar , [2] Munshi N.C. Anderson Jr., L.D. Shah N. Madduri D. Berdeja J. Lonial S. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384: 705-716https://doi.org/10.1056/NEJMoa2024850 Crossref PubMed Scopus (626) Google Scholar ]. Global use of CAR-T therapy in MM is limited. CARTIFAN-1 reported safety and efficacy data on the use of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen–targeting CAR-T therapy, in relapsed/refractory multiple myeloma (RRMM) [ [3] Mi J.Q. Zhao W. Jing H. Fu W. Hu J. Chen L. et al. Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol : official journal of the American Society of Clinical Oncology. 2022; (JCO2200690. Advance online publication)https://doi.org/10.1200/JCO.22.00690 Crossref Scopus (4) Google Scholar ]. The single-arm phase II study reported outcomes of 48 patients who received a cilta-cel infusion in China. The 18-month progression-free survival (PFS) and overall survival (OS) rates were 66.8% and 78.7%, respectively. Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myelomaEuropean Journal of CancerVol. 188PreviewDear Editor, Full-Text PDF" @default.
- W4313334461 created "2023-01-06" @default.
- W4313334461 creator A5042545367 @default.
- W4313334461 creator A5088177143 @default.
- W4313334461 date "2023-03-01" @default.
- W4313334461 modified "2023-09-27" @default.
- W4313334461 title "CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma" @default.
- W4313334461 cites W2013864258 @default.
- W4313334461 cites W2169288585 @default.
- W4313334461 cites W2909894833 @default.
- W4313334461 cites W3133229959 @default.
- W4313334461 cites W3176532045 @default.
- W4313334461 cites W4225108607 @default.
- W4313334461 doi "https://doi.org/10.1016/j.ejca.2022.12.018" @default.
- W4313334461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36680878" @default.
- W4313334461 hasPublicationYear "2023" @default.
- W4313334461 type Work @default.
- W4313334461 citedByCount "1" @default.
- W4313334461 countsByYear W43133344612023 @default.
- W4313334461 crossrefType "journal-article" @default.
- W4313334461 hasAuthorship W4313334461A5042545367 @default.
- W4313334461 hasAuthorship W4313334461A5088177143 @default.
- W4313334461 hasConcept C121608353 @default.
- W4313334461 hasConcept C126322002 @default.
- W4313334461 hasConcept C143998085 @default.
- W4313334461 hasConcept C147483822 @default.
- W4313334461 hasConcept C203014093 @default.
- W4313334461 hasConcept C2776364478 @default.
- W4313334461 hasConcept C2777701055 @default.
- W4313334461 hasConcept C3875195 @default.
- W4313334461 hasConcept C71924100 @default.
- W4313334461 hasConceptScore W4313334461C121608353 @default.
- W4313334461 hasConceptScore W4313334461C126322002 @default.
- W4313334461 hasConceptScore W4313334461C143998085 @default.
- W4313334461 hasConceptScore W4313334461C147483822 @default.
- W4313334461 hasConceptScore W4313334461C203014093 @default.
- W4313334461 hasConceptScore W4313334461C2776364478 @default.
- W4313334461 hasConceptScore W4313334461C2777701055 @default.
- W4313334461 hasConceptScore W4313334461C3875195 @default.
- W4313334461 hasConceptScore W4313334461C71924100 @default.
- W4313334461 hasLocation W43133344611 @default.
- W4313334461 hasLocation W43133344612 @default.
- W4313334461 hasOpenAccess W4313334461 @default.
- W4313334461 hasPrimaryLocation W43133344611 @default.
- W4313334461 hasRelatedWork W2064357373 @default.
- W4313334461 hasRelatedWork W2220102944 @default.
- W4313334461 hasRelatedWork W2333380148 @default.
- W4313334461 hasRelatedWork W2414745257 @default.
- W4313334461 hasRelatedWork W2435227317 @default.
- W4313334461 hasRelatedWork W2591218360 @default.
- W4313334461 hasRelatedWork W3201761585 @default.
- W4313334461 hasRelatedWork W4229026538 @default.
- W4313334461 hasRelatedWork W4380149363 @default.
- W4313334461 hasRelatedWork W4385665607 @default.
- W4313334461 hasVolume "182" @default.
- W4313334461 isParatext "false" @default.
- W4313334461 isRetracted "false" @default.
- W4313334461 workType "article" @default.